Folic acid

The selected oral solution is indicated for folate-deficiency megaloblastic anemia in adult and pediatric patients. Tablet and injection labeling describes such anemia in nutritional deficiency, pregnancy, infancy/childhood and sprue. Folic acid alone does not treat B12-deficiency anemia.

CDC recommends 400 mcg (0.4 mg) folic acid daily for women capable of pregnancy, before and during early pregnancy. A prior neural-tube-defect-affected pregnancy requires a clinician-guided recurrence-prevention plan; this is a public-health recommendation rather than the selected anemia product’s indication.

Oral solution is 0.2 mg/mL (200 mcg/mL): a prescribed 1 mg equals 5 mL. Use an oral syringe for the actual dose, especially children; a 1 mg tablet does not automatically deliver small infant doses. Selected injection is 5 mg/mL: IM, IV or SC may be used when exceptionally severe disease or impaired GI absorption warrants parenteral treatment. Its labeled therapeutic dose is up to 1 mg/day, with individualized higher doses for resistant cases; preservatives impose separate neonatal risks. Do not confuse its concentration with the oral liquid.

General prevention is 400 mcg/day. For women planning another pregnancy after a neural-tube-defect-affected pregnancy, CDC recommends 4,000 mcg (4 mg) daily beginning 1 month before conception through the first 3 months of pregnancy, under clinician guidance. This higher-risk plan is not a universal pregnancy dose. Check the actual folic-acid amount; mcg dietary folate equivalents (DFE) are different units.

Oral solution: prior hypersensitivity to folic acid or ingredients. Selected tablet: previous intolerance to the drug. B12-deficiency anemia is a warning against folic acid alone, not a reason to omit needed B12 treatment. The reviewed injectable label does not provide a separately titled contraindications section; allergy and preservative risks must still be assessed.

The reviewed formulations have no boxed warning. The injection has prominent aluminum and benzyl-alcohol warnings, and all forms can obscure untreated B12-deficiency disease.

Reported reactions include allergy/rash/bronchospasm, GI upset and altered sleep/concentration or other neuropsychiatric symptoms. Some legacy GI/neuropsychiatric reports followed 15 mg/day for a month and should not be presented as rates at ordinary replacement doses. Prolonged therapy may reduce measured B12 and some anticonvulsant-treated patients have increased seizures. For overdose or an unintended high dose, contact Poison Help/medical advice; reassess B12 risk rather than assuming vitamin therapy is harmless.

Folate replacement may decrease phenytoin concentrations or antagonize seizure control; monitor clinically and review levels/dose when appropriate. Anticonvulsants and agents such as sulfasalazine, trimethoprim, pyrimethamine or methotrexate can reduce folate activity/availability; review response and treatment goals. The oral-solution label describes interference with methotrexate/tetracycline absorption and advises separating administration; it does not establish one universal interval. Methotrexate-associated supplementation schedules require the prescriber’s plan. Folic acid is not leucovorin (folinic acid) rescue.

Some antibiotics can give falsely low serum/red-cell folate results with older microbiologic assays by suppressing the assay organism. Tell the laboratory about treatment; do not interpret a single result without the clinical and B12 context.

Long clinical experience has not identified a drug-associated pregnancy risk at appropriate supplementation; folate deficiency early in pregnancy raises neural-tube-defect risk. Distinguish prevention guidance from the 0.8 mg anemia-maintenance regimen. Folic acid is present in milk; recommended supplementation has not produced reported infant adverse effects across decades of use, while milk-production data are lacking. Assess maternal need and deficiency.

The oral-solution label includes pediatric anemia treatment and age-specific maintenance from birth. Use accurate liquid measurement; the selected benzyl-alcohol injection requires special neonatal assessment. No separate fixed geriatric, renal or hepatic adjustment algorithm is supplied by these labels. Kidney impairment increases concern for prolonged parenteral aluminum exposure; dialysis and other disease may also contribute to folate deficiency, so adjust to clinical response.

Folic acid is reduced to active tetrahydrofolate derivatives that participate in purine/thymidylate synthesis. Replacement can restore effective DNA synthesis and normal erythropoiesis in folate-deficient megaloblastic marrow.

Absorption

Primarily proximal small intestine; plasma appearance about 15–30 minutes, peak generally within 1 hour.

Metabolism / distribution

Converted to dihydrofolate, tetrahydrofolate and active folate derivatives; tissue distribution with major liver storage.

Elimination

Folate/metabolites appear in urine; amount excreted varies with dose and stores.

Units / related compounds

Folic acid mass, food folates and mcg DFE are distinct; folic acid and leucovorin are not interchangeable medicines.

Evaluate the anemia’s cause, folate status and B12 before treatment; follow CBC/blood response and neurologic symptoms. Monitor frequently for relapse and adjust maintenance in high-risk states. Review seizure control and relevant anticonvulsant levels, antifolate therapy, and total parenteral excipient exposure. No universal lab interval is invented.

Use prescribed mg/mcg and exact concentration; obtain a syringe for oral liquid. Report rash, breathing trouble, new neurologic symptoms or seizure changes. Discuss pregnancy plans early and review supplements/fortified foods as well as prescriptions. Read the actual folic-acid amount in parentheses on a DFE supplement label; do not take multiple multivitamins to construct a high-risk prevention regimen.

Ingredient / route

Folic acid 0.2 mg/mL · oral solution.

Presentation

Yellow, mixed-berry flavored; amber PET bottle with child-resistant closure.

Labeler

Ayurax, LLC.

Example NDC

69499-501-75 · 75 mL.

U.S. status

Prescription; SPL category NDA authorized generic, not a dietary supplement.

Selected oral solution

0.2 mg/mL (200 mcg/mL).

Selected tablet

1 mg; yellow round convex AN 361 / bisect; Major NDC 0904-7224-61 institutional unit-dose carton of 100; ANDA label.

Selected injection

5 mg/mL (50 mg/10 mL) multidose vial; XGen NDC 39822-1100-1; IM/IV/SC, ANDA label, benzyl alcohol 15 mg/mL.

Scope

Other supplements, methylfolate, folinic acid, prenatal combinations and preservative-free preparations require their exact products; no category is inferred for all folic acid products.

Selected oral liquid: 20–25°C, original container/light protection; discard unused solution 30 days after first opening. Tablet: 20–25°C, protect light/moisture; the selected institutional unit-dose pack is not child resistant and needs appropriate dispensing protection. Injection: 20–25°C, protect light and retain carton until use; inspect for particles/discoloration. Follow exact vial handling rather than inventing an after-opening limit.